Effect of fluconazole on the pharmacokinetics of fuzuloparib: an open-label, crossover study in Chinese healthy male volunteers

Purpose Fuzuloparib (AiRuiYi TM , formerly fluzoparib, SHR3162) is a new orally active poly adenosine diphosphate ribose polymerase (PARP) inhibitor. It has multiple pharmacological activities in breast, ovarian, and prostatic cancer. Fuzuloparib is mainly metabolized through the enzyme CYP3A4 may s...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Cancer chemotherapy and pharmacology Ročník 89; číslo 1; s. 141 - 148
Hlavní autoři:	Chen, Xue, Yang, Feng, Zhao, Jiao, Tang, Qi, Heng, Jianfu, Deng, Jun, Zhang, Jin, Chen, Yong, Li, Kunyan, Wang, Jing
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Berlin/Heidelberg Springer Berlin Heidelberg 01.01.2022 Springer Nature B.V
Témata:	Adenosine Adult Antifungal agents Aspartate transaminase Breast cancer Cancer Research Clinical Trial Report Cross-Over Studies Cytochrome P-450 CYP3A Inhibitors - adverse effects Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics Fluconazole Fluconazole - adverse effects Fluconazole - pharmacokinetics Healthy Volunteers Humans Hyperlipidemia Male Medicine Medicine & Public Health Middle Aged Oncology Ovarian cancer Pharmacokinetics Pharmacology/Toxicology Poly(ADP-ribose) polymerase Poly(ADP-ribose) Polymerase Inhibitors - adverse effects Poly(ADP-ribose) Polymerase Inhibitors - pharmacokinetics Prostate cancer Ribose Transaminase Fluconazole CYP3A4 Drug–drug interaction (DDI) Fuzuloparib PARP inhibitor
ISSN:	0344-5704, 1432-0843, 1432-0843
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!